Vijay Kumar Panthi | Medicine and Health Sciences | Best Researcher Award

Posted on by sciencefather

Mr. Vijay Kumar Panthi | Medicine and Health Sciences | Best Researcher Award

PhD Candidate, Queensland University of Technology, Australia

Vijay Kumar Panthi is a seasoned professional in Pharmaceutics with a focus on drug delivery and formulation. He holds a Master’s degree in Pharmacy (Pharmaceutics) from Mokpo National University, South Korea, and a Bachelor’s degree in Pharmacy from Tribhuvan University, Nepal. With extensive experience in formulation, research, and development, he has worked with several prominent pharmaceutical companies, including Royal Sasa Nepal Pharmaceuticals and Corel Pharmaceuticals. His expertise spans across nanoformulations, drug delivery systems, and formulation development for anticancer and anti-aging treatments. He has also contributed to several publications and conference posters, particularly in the field of nanomedicine, wound healing, and oral drug bioavailability. His research interests center around enhancing drug solubility and permeability, particularly for anticancer and diabetes treatments. He is a registered pharmacist with the Pharmacy Council of Nepal and actively engages in clinical pharmacy training and regulatory affairs.

Profile

Education

Vijay Kumar Panthi completed his Master’s in Pharmacy (Pharmaceutics) from Mokpo National University, South Korea, between 2017-2019. This advanced program deepened his knowledge of drug formulation, nanoformulations, and drug delivery systems. He earned his Bachelor’s degree in Pharmacy from Tribhuvan University, Nepal, at Sunsari Technical College, Dharan, between 2010 and 2014. Additionally, he completed Intermediate studies in Pharmacy at the Nepal Institute of Medical Science and Technology (NIMST), Kathmandu. Before that, he graduated from Mukti Higher Secondary School, Pyuthan, Nepal, in 2005. His academic journey has provided him with a solid foundation in pharmaceutical sciences and research, focusing on developing innovative solutions to improve drug efficacy and bioavailability, particularly in cancer and diabetes therapies.

Experience

Vijay Kumar Panthi has over 10 years of experience in the pharmaceutical industry, spanning formulation development, research, and regulatory affairs. He currently serves as the Manager of Formulation, Research, and Development (FR&D) at Royal Sasa Nepal Pharmaceuticals. Prior to this, he held the same position at Corel Pharmaceuticals Pvt. Ltd., where he developed and tested various drug formulations. His experience also includes conducting formulation and development research at Mokpo National University, South Korea, between 2017 and 2019. Additionally, he worked at Asian Pharmaceuticals Pvt. Ltd., where he contributed to GMP-certified projects, regulatory affairs, and validation processes. He has also participated in industrial training at companies like Everest Pharmaceuticals, Nepal, and Zydus Healthcare, India, which further honed his practical knowledge. Vijay’s diverse experience across multiple pharmaceutical functions highlights his expertise in drug formulation and development, particularly for anticancer and anti-aging applications.

Research Focus

Vijay Kumar Panthi’s primary research interests lie in the formulation of drug delivery systems, particularly for anticancer and diabetes treatments. His work focuses on enhancing the solubility, permeability, and bioavailability of active pharmaceutical ingredients (APIs), particularly those with limited oral bioavailability. In his Master’s thesis, he worked on the co-delivery system of pemetrexed and quercetin via multiple nanoemulsions to improve oral bioavailability and anticancer efficacy. His interest in nanoformulations extends to other therapeutic areas such as wound healing and anti-aging. By utilizing nanoemulsions, liposomes, and hydrogels, Vijay aims to develop novel drug delivery systems that improve the therapeutic outcomes of drugs for various diseases, especially chronic conditions like cancer and diabetes. His research on the formulation of anti-acne treatments and serine protease formulations for inflammation also demonstrates his versatility and commitment to improving patient care through scientific advancements.

Publication Top Notes

  1. Characterization and In Vivo Evaluation of an Oral Multiple Nanoemulsive System for Co-Delivery of Pemetrexed and Quercetin 📚💊
  2. Preparation, Characterization, and Biological Activities of Topical Anti-Aging Ingredients in a Citrus junos Callus Extract 🍊💆‍♂️
  3. Formulation and Development of Adapalene Topical Nanohydrogel Using Different Surfactants and Cosurfactants for Antiacne Activity: In Vitro and Ex Vivo Evaluation 🧴🔬
  4. Enhanced Oral Absorption of Pemetrexed by Ion-Pairing Complex Formation with Deoxycholic Acid Derivative and Multiple Nanoemulsion Formulations 💊🧪
  5. Formulation and Development of Serratiopeptidase Enteric Coated Tablets and Analytical Method Validation by UV Spectroscopy 🧫🔬
  6. A Validated RP-HPLC Method for Simultaneous Determination of Cefixime and Clavulanic Acid Powder in Pediatric Oral Suspension 🧪👶
  7. Preparation and Characterization of Callus Extract From Pyrus pyrifolia and Investigation of Its Effects on Skin Regeneration 🍐🧴
  8. Formulation and Development of Water-in-Oil Emulsion-Based Luliconazole Cream: In Vitro Characterization and Analytical Method Validation by RP-HPLC 🧴🔬

 

 

Wijdan Al-Ahmadi | Biomedicine | Best Researcher Award

Posted on by sciencefatherLeave a Comment on Wijdan Al-Ahmadi | Biomedicine | Best Researcher Award

Dr. Wijdan Al-Ahmadi | Biomedicine | Best Researcher Award

Associate scientest, King Faisal specialist hospital and research center, Saudi Arabia

Dr. Wijdan Al-Ahmadi is a seasoned researcher with over 20 years of experience in biomedicine, focusing on cancer biology, immunology, and disease mechanisms. Based in Riyadh, Saudi Arabia, she is a key member of the Molecular Biomedicine Research Department at King Faisal Specialist Hospital and Research Center. Her work spans diverse fields, including inflammatory diseases and cardiovascular research. Notably, in 2023, she contributed to a groundbreaking experiment aboard the International Space Station (ISS), highlighting her ability to conduct research in extreme environments. Dr. Al-Ahmadi has demonstrated leadership through her work as an educator, mentoring students at various academic levels. Her contributions continue to push the boundaries of biomedicine, paving the way for new therapeutic strategies and personalized medicine approaches.

Profile

Education

Dr. Wijdan Al-Ahmadi holds a Ph.D. in Bioscience from Cardiff University (2015–2019), where she focused on cancer and immunology research. She also earned a B.Sc. in Biochemistry from King Saud University (1994–1998). Her academic journey has equipped her with advanced expertise in molecular biology, cancer research, and biomedical sciences. Dr. Al-Ahmadi’s educational foundation is complemented by her extensive hands-on experience in laboratory settings, which has enabled her to contribute to numerous pioneering studies. Through her formal education and continuous professional development, she has maintained a passion for unraveling disease mechanisms and enhancing health outcomes through scientific innovation.

Experience

Dr. Al-Ahmadi’s career spans over two decades in the field of biomedicine. She currently serves as an Associate Scientist at King Faisal Specialist Hospital and Research Center in Riyadh, where she leads advanced research projects in cancer biology and immunology. Prior to this, she was a Post-doctoral Fellow (2020–2023), focusing on cancer and inflammatory disease mechanisms. Dr. Al-Ahmadi’s experience includes roles as a Research Assistant (2007–2015) and a Research Technician (2002–2006), where she was deeply involved in cancer research and molecular biology assays. She has also mentored Ph.D., master’s, and undergraduate students throughout her career. Her research has had significant impact both in clinical settings and in experimental fields, including innovative studies aboard the ISS in 2023, demonstrating her versatility in different research environments.

Research Focus

Dr. Wijdan Al-Ahmadi’s research is focused on understanding the underlying mechanisms of diseases, particularly cancer, inflammatory disorders, and cardiovascular diseases. She is dedicated to uncovering how specific genetic mutations and signaling pathways contribute to disease progression, aiming to identify novel therapeutic targets for better patient outcomes. Dr. Al-Ahmadi’s work in space science is also notable, having contributed to microgravity research aboard the ISS, exploring how human physiology and disease processes respond in space. Her findings not only have applications for space health but also provide critical insights that can benefit human health on Earth. She is driven by the potential of personalized medicine and therapeutic interventions that address the root causes of disease.

Publication Top Notes

  1. Pro-atherogenic actions of signal transducer and activator of transcription 1 serine 727 phosphorylation in LDL receptor deficient mice via modulation of plaque inflammation. 🧬🔬
  2. Protective effects of a unique combination of nutritionally active ingredients on risk factors and gene expression associated with atherosclerosis in C57BL/6J mice fed a high-fat diet. 🥗🧪
  3. Posttranscriptional control of the chemokine receptor CXCR4 expression in cancer cells. 🧑‍🔬🦠
  4. miR-29a inhibition normalizes HuR over-expression and aberrant AU-rich mRNA stability in invasive cancer. 🧬💡
  5. The RNA-binding zinc-finger protein tristetraprolin regulates AU-rich mRNAs involved in breast cancer-related processes. 🔬💥
  6. Alternative polyadenylation variants of the RNA binding protein, HuR: abundance, role of AU-rich elements and auto-Regulation. 🧬📊
  7. Cloning-free regulated monitoring of reporter and gene expression. 🧬🧑‍🔬
  8. RNase L downmodulation of the RNA-binding protein, HuR, and cellular growth. 🔬🧑‍🔬
  9. Bioinformatics and experimental derivation of an efficient hybrid 3′ untranslated region and use in expression active linear DNA with minimum poly(A) region. 💻🧬
  10. Expedient liquid chromatographic method with fluorescence detection for montelukast sodium in micro-samples of plasma. 🧪💉

 

 

 

Michael Wang | Mantle Cell Lymphoma | Best Researcher Award

Posted on by sciencefatherLeave a Comment on Michael Wang | Mantle Cell Lymphoma | Best Researcher Award

Prof. Dr. Michael Wang | Mantle Cell Lymphoma | Best Researcher Award

Lymphoma/Myeloma Dept, MD Anderson Cancer Center, United States

Dr. Michael Wang, MD, is a distinguished physician and researcher specializing in lymphoma, myeloma, and stem cell transplantation. He is currently a Professor at The University of Texas MD Anderson Cancer Center, where he has been serving since 2013. Dr. Wang has made significant contributions to the field, particularly in the understanding and treatment of lymphoma and myeloma. He holds multiple state licenses, including Arizona, Alabama, and Georgia, and has a wealth of experience in oncology and hematology. Dr. Wang’s work is highly recognized, earning him several prestigious awards, such as the “Top Doctor” award in 2020. He also directs the Mantle Cell Lymphoma Program of Excellence at MD Anderson, and serves as a co-principal investigator on the B-cell Lymphoma Moonshot Project. His professional efforts are complemented by his active participation in numerous research initiatives aimed at improving patient outcomes.

Profile

Scopus

Education 

Dr. Wang obtained his Medical Doctorate (MD) from Shandong Medical University, China, in 1985. He furthered his education with a Master’s in Physiology from Beijing Medical University in 1988. He later completed several fellowships and specialized training in the United States. Dr. Wang pursued a medical oncology/hematology fellowship at The University of Texas MD Anderson Cancer Center from 1999 to 2002. Prior to this, he worked as an attending physician at Kelsey-Seybold Clinic, Houston, from 1998 to 1999. His early career also saw him at Yale-Norwalk Hospital, where he completed his residency in medicine (1995–1997) and served as Chief Medical Resident (1997–1998). Additionally, Dr. Wang gained valuable experience through visiting fellowships at the National Institutes of Health (NIH), where he conducted research in molecular biology and cell biology. His academic foundation has laid the groundwork for his transformative contributions to lymphoma and hematology.

Experience 

Dr. Wang’s clinical and research career has spanned multiple prestigious institutions. Since joining The University of Texas MD Anderson Cancer Center in 2013, he has served as a Professor in the departments of Lymphoma/Myeloma and Stem Cell Transplantation. He currently holds the Puddin Clarke Professorship in Multiple Myeloma Research. Additionally, he co-leads the B-cell Lymphoma Moonshot Project and directs the Mantle Cell Lymphoma Program of Excellence. His academic journey began with notable fellowships and residencies, which included time spent at Yale-Norwalk Hospital and The University of Michigan Hospitals. Over the years, Dr. Wang has developed expertise in lymphoma, hematology, and stem cell transplantation, which he applies in his clinical practice. His leadership in pioneering research and clinical trials has positioned him as a thought leader in lymphoma and myeloma treatment, driving innovations in patient care and therapeutic strategies.

Awards and Honors 

Dr. Michael Wang’s exemplary career has earned him numerous prestigious awards and honors. In 2020, he was named a “Top Doctor,” recognizing his outstanding clinical expertise. In 2017, he received the Outstanding Service Award from the Chinese American Hematologist Oncologist Network. Dr. Wang was also recognized by the U.S. Congress in 2016 with a Certificate of Special Congressional Recognition for his invaluable contributions to the community. Among his academic distinctions, Dr. Wang received the Otis W. and Pearl L. Walters Faculty Achievement Award in Clinical Research in 2016. He also received the Waun Ki Hong Award for Excellence in Team Science from MD Anderson Cancer Center in 2015. His consistent recognition reflects his leadership and significant impact on clinical research in hematology and oncology. These accolades underline his contributions to the medical field and his commitment to advancing cancer treatment.

Research Focus

Dr. Michael Wang’s research focuses primarily on the treatment and understanding of lymphoma, myeloma, and stem cell transplantation. His work addresses therapeutic strategies in B-cell lymphomas and the molecular mechanisms underlying mantle cell lymphoma. As the director of the Mantle Cell Lymphoma Program of Excellence at MD Anderson, he is at the forefront of exploring novel therapies to improve patient outcomes. His research also delves into resistance mechanisms in mantle cell lymphoma, particularly focusing on the HSP90-MYC-CDK9 network. Additionally, Dr. Wang has contributed significantly to the development of immunotherapies, including CAR-T cell therapies. His work in clinical trials explores the safety and efficacy of combining targeted therapies with traditional treatments. Through his role in the B-cell Lymphoma Moonshot Project, Dr. Wang is driving efforts to accelerate breakthroughs in lymphoma treatment. His research has the potential to transform patient care by identifying personalized, more effective therapies.

Publications

  1. TP53 mutation is frequent in mantle cell lymphoma with EZH2 expression and have dismal outcome when both are present 🧬💔
  2. SOX11+ Large B-Cell Neoplasms: Cyclin D1-Negative Blastoid/Pleomorphic Mantle Cell Lymphoma or Large B-Cell Lymphoma? 🧪🔬
  3. The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma 💊💡
  4. Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001 🧑‍🔬📊
  5. CD5 deletion enhances the antitumor activity of adoptive T cell therapies 💉🦠
  6. Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma 🚀🧬
  7. Inhibition of SRC-3 as a potential therapeutic strategy for aggressive mantle cell lymphoma 🚫🎯

Yousif Kariri | Cancer | Best Researcher Award

Posted on by sciencefatherLeave a Comment on Yousif Kariri | Cancer | Best Researcher Award

Dr Yousif Kariri | Cancer | Best Researcher Award

Assistant Professor , Shaqra University , Saudi Arabia

Dr. Y.A. Kariri is a Saudi researcher and academic, currently an Assistant Professor at Shaqra University’s College of Applied Medical Sciences in Saudi Arabia. Born in Jazan on February 11, 1988, he has an extensive academic and professional background spanning multiple countries. He earned a BSc in Clinical Laboratory Science from King Khalid University, an MSc in Medical Laboratory Sciences from RMIT University (Australia), and a PhD in Pathology from the University of Nottingham (UK). Dr. Kariri has expertise in cancer research, particularly in breast cancer, and is an active member of multiple pathology societies. As the Head of Online Learning and Learning Resources at Shaqra University, he has demonstrated leadership in academic administration. He has been instrumental in driving scientific research initiatives and is also an expert in cell culture and data analysis. Dr. Kariri is passionate about integrating advanced research methodologies in education.

Profile

Strengths for the Award

  1. Advanced Educational Qualifications:
    • PhD in Pathology (University of Nottingham, UK, 2022) — This is a high-level qualification and highlights a solid foundation in scientific research.
    • Master’s and Bachelor’s Degrees — The individual has international experience, having studied in Australia and the UK, further enhancing their research capacity and global perspective.
  2. Relevant and Impactful Research Contributions:
    • Publications in High-Impact Journals:
      • The individual has contributed to several peer-reviewed journal articles in oncology, specifically breast cancer research, with multiple publications in reputable journals like Cancers, Breast Cancer Research and Treatment, and Pathobiology. These contributions are significant, especially the involvement in studies that examine molecular mechanisms of breast cancer and biomarkers in cancer prognosis.
      • Notable publications include research on gene expression, prognostic biomarkers, and lymphovascular invasion, areas critical to advancing cancer diagnostics and treatment.
      • Articles such as “Mechanistic and Clinical Evidence Supports a Key Role for Cell Division Cycle Associated 5 (CDCA5) as an Independent Predictor of Outcome in Invasive Breast Cancer” demonstrate a deep engagement with molecular pathology.
  3. Leadership and Experience in Academia:
    • The individual has held multiple leadership roles at Shaqra University, including Head of Online Learning and Learning Resources and Head of Student Activities, demonstrating the ability to lead teams and enhance educational outcomes.
    • They have also served as an Assistant Professor and have experience in both teaching and curriculum development, particularly in clinical laboratory sciences.
  4. Interdisciplinary Expertise:
    • Expertise in cell culture (in vitro), data analysis (SPSS, PRISM, Cluster analysis), and experience as a medical technologist adds practical knowledge to the research profile, helping bridge the gap between laboratory work and applied medical sciences.
    • Involvement in the Scientific Research Committee and as a publication reviewer in cancer research journals showcases their ability to critically engage with current scientific work and contribute to advancing the field.
  5. International Exposure:
    • Having studied and worked in three different countries (Saudi Arabia, Australia, and the UK), this individual brings a broad, international perspective to their research and teaching, enhancing their academic and professional profile.

Areas for Improvement

  1. Broader Research Collaborations:
    • While the individual has excellent research experience, their publications appear to focus primarily on breast cancer. Exploring broader collaborations in other areas of oncology or interdisciplinary research could further enhance their visibility and impact in the scientific community.
    • Expanding collaborations with international research institutions or leading cancer centers could also broaden the scope and depth of their research, potentially leading to larger-scale, multicentric studies.
  2. Increased Research Grant Applications:
    • The individual’s profile does not mention securing significant research funding or grants. Applying for competitive research grants could enhance the individual’s research capacity and provide more opportunities for large-scale projects, particularly in the area of cancer research.
  3. Further Outreach and Public Engagement:
    • Engaging more with the public or policy-making bodies through science communication efforts, public lectures, or collaborations with healthcare professionals could raise awareness about their research and broaden its impact beyond academia.

Education 

Dr. Y.A. Kariri’s educational journey has been both diverse and international. He completed his BSc in Clinical Laboratory Science from King Khalid University (2011), laying the foundation for his career in laboratory sciences. He then pursued an MSc in Medical Laboratory Sciences from the Royal Melbourne Institute of Technology University (RMIT) in Australia (2017), where he honed his skills in molecular biology and pathology. To further his research aspirations, Dr. Kariri earned a PhD in Pathology from the University of Nottingham (UK) in 2022, where his research focused on the molecular mechanisms behind breast cancer and lymphovascular invasion. Alongside his formal education, Dr. Kariri participated in various professional development programs, including a Higher Education Developer Diploma from the University of Nottingham (2022), which enhanced his teaching and academic leadership skills.

Experience

Dr. Y.A. Kariri has a rich blend of academic and research experience. He began his professional journey with a one-year internship at King Fahad Hospital in Jazan (2010-2011), where he gained hands-on experience in clinical laboratory operations. He then pursued an MSc project at RMIT University, focusing on medical laboratory sciences (2017). Since joining Shaqra University in 2017, Dr. Kariri has taken on several significant roles, including Secretary of the Scientific Council (2017-2018). In 2022, he became an Assistant Professor at the College of Applied Medical Sciences, where he continues to teach and conduct research. He has also served as the Head of Online Learning and Learning Resources and Head of Students Activities at Shaqra University (2022–2024). In addition, Dr. Kariri is a member of the Scientific Research Committee and has extensive experience in cell culture and data analysis.

Awards and Honors

Dr. Y.A. Kariri has been the recipient of several prestigious awards and honors, recognizing his academic and research excellence. He was awarded the King Abdullah Scholarship Program (2008-2011) for his master’s degree, an honor that allowed him to pursue advanced studies at RMIT University in Australia. He was also a PhD Scholar from Shaqra University in Saudi Arabia, enabling his research on breast cancer molecular mechanisms. His international educational background and research contributions have earned him recognition within the academic community. As a researcher, he has been honored with invitations to serve as a publication reviewer for several high-impact journals focusing on oncology and pathology. His leadership roles at Shaqra University, particularly in advancing online learning and student activities, have further cemented his reputation as an influential educator and scholar.

Research Focus 

Dr. Y.A. Kariri’s research focuses primarily on breast cancer and its molecular mechanisms, with an emphasis on lymphovascular invasion (LVI) and related prognostic biomarkers. His PhD project at the University of Nottingham (UK) explored the molecular genes driving breast cancer and their role in LVI, a key factor in cancer metastasis and poor prognosis. His work has been instrumental in identifying and validating novel biomarkers and gene signatures that could serve as therapeutic targets and predictive indicators for cancer progression. His studies have contributed to the broader understanding of cancer cell migration, gene expression, and the molecular complexity of invasive cancer. Dr. Kariri is skilled in cell culture (in vitro) and advanced data analysis, using tools like SPSS, PRISM, and Cluster Analysis to extract meaningful insights from experimental data. His research continues to bridge the gap between molecular biology and clinical application in cancer therapy.

Publications

  1. The role of the ALKBH5 RNA demethylase in invasive breast cancer 🧬🔬
  2. Clinical and molecular significance of the RNA m6A methyltransferase complex in prostate cancer 🔬📊
  3. Mechanistic and Clinical Evidence Supports a Key Role for Cell Division Cycle Associated 5 (CDCA5) as an Independent Predictor of Outcome in Invasive Breast Cancer 🧪📑
  4. Ubiquitin-conjugating enzyme 2C (UBE2C) is a poor prognostic biomarker in invasive breast cancer 💉📉
  5. The itim-containing receptor: Leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) modulates immune response and confers poor prognosis in invasive breast carcinoma 🧫💥
  6. The prognostic significance of interferon-stimulated gene 15 (ISG15) in invasive breast cancer 🧬📈
  7. Molecular Complexity of Lymphovascular Invasion: The Role of Cell Migration in Breast Cancer as a Prototype 🔬🌱
  8. Prognostic significance of KN motif and ankyrin repeat domains 1 (KANK1) in invasive breast cancer 🧬🔍
  9. Utility of ankyrin 3 as a prognostic marker in androgen-receptor‑positive breast cancer 🔬⚖️
  10. A key genomic subtype associated with lymphovascular invasion in invasive breast cancer 🧪🧬

Conclusion

This individual is undoubtedly a strong candidate for the Best Researcher Award based on their extensive academic background, significant contributions to cancer research, and leadership in higher education. Their research has direct implications for cancer diagnostics, prognosis, and treatment, with a focus on the molecular mechanisms that drive breast cancer, making them highly relevant to current healthcare challenges.Their strengths in academic leadership, combined with their technical expertise in laboratory sciences, make them a well-rounded and capable researcher. However, expanding their research horizons, applying for larger research grants, and further increasing their public engagement could elevate their profile even further.

Jorge Amador Berlanga-Acosta | Medicine and Health Sciences | Best Researcher Award

Posted on by sciencefatherLeave a Comment on Jorge Amador Berlanga-Acosta | Medicine and Health Sciences | Best Researcher Award

Prof Dr Jorge Amador Berlanga-Acosta | Medicine and Health Sciences | Best Researcher Award

Research project leader, Center for Genetic Engineering and Biotechnology, Cuba

Dr. Jorge Amador Berlanga Acosta is a distinguished Cuban veterinary medicine and pharmaceutical scientist, born on October 11, 1962, in Bayamo, Granma, Cuba. With a career spanning over three decades, he specializes in the pharmacological applications of Epidermal Growth Factor (EGF) for wound healing and diabetic foot ulcers. He holds several prestigious titles, including Member of Honor of the Cuban National Academy of Science and Distinguished Professor at the University of Electronic Science and Technology of China. Dr. Berlanga has made significant contributions to biomedical research and has been instrumental in various clinical trials and technical missions across multiple continents, earning recognition for his impactful work in regenerative medicine and pharmacology. His expertise is complemented by a strong commitment to education and mentorship in the scientific community. 🌟

Profile

Google Scholar

Strengths for the Award

  1. Extensive Education and Training: Dr. Berlanga has a solid academic background with a Doctor of Veterinary Medicine and a Ph.D. in Pharmaceutical Sciences and Pharmacology. His post-doctoral fellowships at prestigious institutions like the University of Alberta and Imperial Cancer Research Fund highlight his commitment to advancing medical knowledge.
  2. Research Contributions: His extensive work on epidermal growth factor (EGF) and its applications in wound healing, particularly in diabetic foot ulcers, is groundbreaking. He has led numerous research projects and has a substantial number of publications in reputable journals, indicating his active engagement in critical biomedical research.
  3. Recognition and Awards: Dr. Berlanga has received numerous prestigious awards, including the “HĂŠroe del Trabajo de la RepĂşblica de Cuba” and various international recognitions, showcasing his impact and contributions to the field.
  4. Leadership in Scientific Community: His roles in coordinating research commissions, leading projects, and serving as a speaker at over 40 international conferences illustrate his leadership and influence in the scientific community.
  5. Multidisciplinary Approach: His research spans various aspects of pharmacology, tissue repair, and regenerative medicine, demonstrating his ability to integrate knowledge across disciplines effectively.
  6. International Collaboration: Dr. Berlanga’s involvement in international workshops and conferences shows his commitment to collaboration and the dissemination of knowledge globally.

Areas for Improvement

  1. Broader Research Scope: While Dr. Berlanga’s focus on EGF is significant, exploring additional areas of research could enhance his impact. Diversifying his research portfolio may lead to novel insights and applications in other fields of medicine.
  2. Public Engagement and Communication: Increasing his outreach efforts to communicate research findings to the general public could enhance the visibility of his work and its implications for healthcare.
  3. Mentorship Opportunities: Engaging more with younger researchers and students through mentorship programs could foster the next generation of scientists and broaden the research community’s perspectives.
  4. Interdisciplinary Collaboration: Further collaboration with other scientific disciplines, such as engineering or technology, could lead to innovative approaches in his research areas.

Education

Dr. Berlanga’s educational journey began with primary education in Bayamo, Granma, followed by secondary schooling. He obtained his Doctor of Veterinary Medicine from the Universidad de Granma in 1985. He furthered his studies with a PhD in Pharmaceutical Sciences and Pharmacology from the Universidad de La Habana in 2000. His academic pursuits included post-doctoral fellowships at renowned institutions, such as the University of Alberta in Canada and the Leicester General Hospital in the UK, focusing on wound healing and gastroenterology. Additionally, he completed numerous specialization courses in clinical pathology, molecular biology, and experimental pharmacology. His diverse educational background has equipped him with the knowledge and skills to advance biomedical research and contribute to the field significantly. 🎓

Experience

Dr. Berlanga’s professional experience includes roles as an instructor and assistant lecturer in Anatomical Pathology at the Universidad de Granma and as an Associate Professor of Pathology. He has been a researcher at the Centro de IngenierĂ­a GenĂŠtica y BiotecnologĂ­a (CIGB) in Havana, focusing on EGF’s pharmacological effects and wound healing mechanisms. Over the years, he has led various departments and projects within CIGB, including preclinical studies and diabetic foot ulcer healing initiatives. His leadership has driven significant advancements in understanding tissue repair and regeneration. In addition to his research, Dr. Berlanga has been a prominent speaker at numerous international conferences, sharing his findings and fostering collaboration in the scientific community. His extensive experience has established him as a leading figure in the field of biomedical sciences. 🔬

Awards and Honors

Dr. Berlanga’s contributions to science have earned him numerous accolades. He received the Alberta Heritage Foundation Scholarship in 1995 and the Royal Society Annual Award in 1998. In 2011, he was honored with the DistinciĂłn Carlos J. Finlay and recognized by the World Intellectual Property Organization as the best young inventor. His achievements include being named Hijo Ilustre de Granma and Bayamo, as well as receiving the prestigious title of HĂŠroe del Trabajo de la RepĂşblica de Cuba in 2020. He has also been acknowledged as a Distinguished Professor at the University of Electronic Science and Technology of China. These awards highlight his significant impact on science and society through innovative research and dedication to education. 🏆

Research Focus

Dr. Berlanga’s research primarily focuses on the pharmacological applications of Epidermal Growth Factor (EGF) in wound healing and tissue regeneration. His investigations have led to the development of various animal models to study EGF’s effects on diabetic foot ulcers, ischemia/reperfusion injury, and gastrointestinal health. He explores the molecular mechanisms underlying EGF’s protective properties and its role in enhancing healing processes. His work also includes studying cellular pathologic memory and its implications in diabetes and wound chronicity. Dr. Berlanga’s commitment to advancing regenerative medicine continues to shape therapeutic strategies for complex wound healing challenges, making significant contributions to biomedical science. 🧬

Publication Top Notes

  • Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis
  • The pro‐inflammatory environment in recalcitrant diabetic foot wounds
  • Intra‐lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo …
  • Epidermal growth factor in clinical practice–a review of its biological actions, clinical indications and safety implications
  • Intralesional administration of epidermal growth factor‐based formulation (Heberprot‐P) in chronic diabetic foot ulcer: treatment up to complete wound closure
  • Intralesional injections of Citoprot‐PÂŽ (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation
  • Glucose toxic effects on granulation tissue productive cells: the diabetics’ impaired healing
  • Epidermal growth factor intralesional infiltrations can prevent amputation in patients with advanced diabetic foot wounds
  • Diabetic foot ulcers and epidermal growth factor: revisiting the local delivery route for a successful outcome
  • Gastrointestinal cell proliferation and crypt fission are separate but complementary means of increasing tissue mass following infusion of epidermal growth factor in rats
  • Diabetic lower extremity wounds: the rationale for growth factors‐based infiltration treatment
  • Healing enhancement of diabetic wounds by locally infiltrated epidermal growth factor is associated with systemic oxidative stress reduction
  • Cellular senescence as the pathogenic hub of diabetes-related wound chronicity
  • Wound chronicity, impaired immunity and infection in diabetic patients
  • Insulin resistance at the crossroad of Alzheimer disease pathology: A review
  • Potency and stability of C terminal truncated human epidermal growth factor
  • Systemic translation of locally infiltrated epidermal growth factor in diabetic lower extremity wounds
  • Epidermal growth factor (EGF) and platelet-derived growth factor (PDGF) as tissue healing agents: clarifying concerns about their possible role in malignant transformation and …
  • Intestinal growth in parenterally‐fed rats induced by the combined effects of glucagon‐like peptide 2 and epidermal growth factor
  • Medical practice confirms clinical trial results of the use of intralesional human recombinant epidermal growth factor in advanced diabetic foot ulcers

Conclusion

Dr. Jorge Amador Berlanga Acosta exemplifies the qualities of an outstanding researcher through his extensive educational background, significant contributions to science, and recognized leadership. His innovative work on EGF and wound healing positions him as a strong candidate for the Best Researcher Award. By broadening his research scope, enhancing public engagement, and fostering mentorship, he can further elevate his impact on the scientific community and society at large.